Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX.

Jinkook KimEunjeong JiKwangrok JungIn Ho JungJaewoo ParkJong-Chan LeeJin Won KimJin-Hyeok HwangYong-Tae Kim

Published in: Journal of personalized medicine (2021)

Female patients showed longer OS despite a more rapid dose reduction during each cycle. Gender differences should be considered during FOLFIRINOX treatment.

Keyphrases

end stage renal disease
ejection fraction
locally advanced
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
radiation therapy
patient reported outcomes
patient reported